Coronavirus: Commission completes vaccines portfolio following talks with a sixth manufacturer
The European Commission yesterday concluded exploratory talks with BioNTech-Pfizer to purchase a potential vaccine against COVID-19. BioNTech-Pfizer is the sixth company with which the Commission has concluded talks, following Sanofi-GSK on 31 July, Johnson & Johnson on 13 August, CureVac on 18 August and Moderna on 24 August. The first contract, signed with AstraZeneca, entered into force on 27 August.
The envisaged contract with BioNTech-Pfizer would provide for the possibility for all EU Member States to purchase the vaccine, as well as to donate to lower and middle income countries or re-direct to European countries. It is anticipated that the Commission will have a contractual framework in place for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to purchase up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.
Ursula von der Leyen, President of the European Commission, yesterday said:
“I am happy to announce that we have concluded talks with BioNTech-Pfizer for an initial purchase of 200 million doses of future coronavirus vaccines. This is the 6th pharma company with which we have concluded talks or signed an agreement for potential vaccines, in record time. Our chances to develop and deploy a safe and effective vaccine have never been higher, both for Europeans here at home, or for the rest of the world. To defeat coronavirus anywhere, we need to defeat it everywhere.”
Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:
“Today's final talks with BioNTech-Pfizer is yet another important step in our efforts to build a sound and diverse portfolio of vaccine candidates. This was the objective of our EU Vaccine Strategy, and we are delivering on it. We are optimistic that among these candidates there will be a safe and effective vaccine against COVID-19 to help us defeat this pandemic.”
BioNTech is a German company working with US-based Pfizer to develop a new vaccine based on messenger RNA (mRNA). mRNA plays a fundamental role in human biology, transferring the instructions which direct cells in the body to make proteins to prevent or fight disease.
The exploratory talks concluded yesterday are intended to result in an Advance Purchase Agreement to be financed with the Emergency Support Instrument, which has funds dedicated to the creation of a portfolio of potential vaccines with different profiles and produced by different companies.
Latest News from
ESMA Consults on Fees For Benchmarks Administrators28/09/2020 09:25:00
The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, recently (25 September 2020) launched a consultation on fees for benchmarks administrators under the BMR.
Statement by Executive Vice-President Margrethe Vestager on the Commission's decision to appeal the General Court's judgment on the Apple tax State aid case in Ireland25/09/2020 15:25:00
Statement given by Executive Vice-President Margrethe Vestager on the Commission's decision to appeal the General Court's judgment on the Apple tax State aid case in Ireland.
Why is Parliament calling for new EU revenue-raising powers?25/09/2020 14:33:00
Parliament is calling for new EU revenue sources to invest in Europe’s future and support the Covid-19 recovery without burdening taxpayers.
Hong Kong: Statement by the Spokesperson on the arrest of Joshua Wong and other pro-democracy activists25/09/2020 13:25:00
The arrest of Hong Kong pro-democracy activist Joshua Wong on 24 September is the latest in a troubling series of arrests of pro-democracy activists since the summer.
ESMA Consults On MIFIR Reference Data And Transaction Reporting25/09/2020 12:38:00
The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, yesterday launched a Consultation Paper (CP) reviewing the reference data and transaction reporting obligations under the Market in Financial Instruments Regulation (MiFIR).
MEPs question whether the new Migration Pact will bring about real change25/09/2020 11:33:00
The new Migration Pact is insufficient for the majority of EP groups. Some demand compulsory relocation of refugees; others want a firmer stance on irregular arrivals.
Questions and Answers: Coronavirus and the EU Vaccines Strategy25/09/2020 09:25:00
On 17 June, the European Commission presented a European strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19.
European Centre for Disease Prevention and Control's new risk assessment shows need to step up coronavirus response in the EU24/09/2020 17:02:00
Today, the European Centre for Disease Prevention and Control (ECDC) published its updated risk assessment regarding the COVID-19 pandemic, alongside a set of guidelines for non-pharmaceutical interventions (such as hand hygiene, physical distancing, cleaning and ventilation).
Artificial intelligence: threats and opportunities24/09/2020 16:33:00
Artificial intelligence (AI) affects our lives more and more. Learn about the opportunities and threats for security, democracy, businesses and jobs.